Clinical Studies

SYNERGY™ Stent: Addressing the Full Spectrum of Cardiovascular Disease Complexity

Supporting research of the SYNERGY™ Stent

The SYNERGY™ Stent Clinical Program and research is studying approximately 20,000 patients in a wide variety of trials and will explore many types of patient populations. This research is designed to truly reflect the situations that interventional cardiologists experience every day in the cath lab.

Learn more

Physician Experience

Dr. Keith Dawkins and Dr. Craig Thompson

Global Chief-Medical-Officer, Dr. Keith Dawkins and U.S. Chief-Medical-Officer, Dr. Craig Thompson, discuss the compelling body of clinical and real-world evidence to support the safety of the SYNERGY™ Stent.

Learn more

Safety Highlighted with the SYNERGY™ Stent System in the EVOLVE 5-Year Trial Data

Long-term Safety with the SYNERGY™ Stent System

The EVOLVE 5-Year Data presented at EuroPCR 2016 showed the Long-term Safety with the SYNERGY™ Stent System.

Learn more

SYNERGY™ Stent reported lowest rates of ST in real-world SCAAR registry

Lowest Rates of Stent Thrombosis in Real-World SCAAR Registry

In this real-world registry1 of over 83,000 patients the SYNERGY stent’s thin strut design and bioabsorbable polymer coating show a trend of lower definite stent thrombosis compared to the other bioabsorbable polymer and permanent polymer drug-eluting stents.

Learn more

SYNERGY™ Low Event Rates after Early DAPT Discontinuation in Complex Patients

Belfast study

In a retrospective, single-center analysis of 100 extremely complex patients from Belfast, Ireland, the use of the SYNERGY™ stent allowed for early discontinuation of DAPT, without an increase in the incidence of stent thrombosis, MI and cardiac death at 12 Months.

Learn more

Further Information